Clovis Oncology Inc.'s PARP inhibitor Rubraca is showing promise in prostate cancer, according to data released at this year’s ESMO conference, as the company hopes to steal a march on AstraZeneca PLC and Merck & Co. Inc.’s more established rival drug.
Clovis In Pole Position To Be First PARP For Prostate Cancer
Clovis is looking a steal a march on its rival PARP inhibitors and hopes to be the first drug in the class to get approval for prostate cancer following strong data seen in the TRITON trial.
More from R&D
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from Scrip
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.